MoST study shows promise of precision medicine – Professor David Thomas

Thousands of Australian cancer patients are accessing genome-directed therapies via a national precision oncology program, with many seeing positive results, Garvan Institute of Medical Research Kinghorn Cancer Centre Director Professor David Thomas told the COSA 2021 Annual Scientific Meeting. The Molecular Screening and Therapeutics (MoST) study, run through Professor Thomas’ company Omico, aims to improve ...

Already a member?

Login to keep reading.

© 2022 the limbic